Foenumoside B from Lysimachia foenum-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet

详细信息    查看全文

• 作者：Jong Bae Seo^a ; ¹ ; Sang Wook Park^a ; ¹ ; Sung Sik Choe^a ; ¹ ; Hyun Woo Jeong^b ; Jae Young Park^a ; Eun-Wook Choi^a ; Dong-Seung Seen^a ; Jae-Yeon Jeong^c ; ^{jeongjy@kordi.re.kr} ; Tae Gyu Lee^a ; ^{tglee17@gmail.com}
• 关键词：Obesity ; Foenumoside B ; Lysimachia foenum-graecum ; High-fat diet ; AMPK ; PPAR¦Ã
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2012
• 出版时间：13 January 2012
• 年：2012
• 卷：417
• 期：2
• 页码：800-806
• 全文大小：651 K

文摘

We have previously reported anti-obesity effects of Lysimachia foenum-graecum in high-fat diet (HFD)-induced obesity model. Here we isolated a triterpene saponin foenumoside B as an active component of L. foenum-graecum. Foenumoside B blocked the differentiation of 3T3-L1 preadipocytes in a dose-dependent manner with an IC50 of 0.2 ¦Ìg/ml in adipogenesis assay and suppressed the induction of PPAR¦Ã, the master regulator of adipogenesis. Foenumoside B induced the activation of AMP-activated protein kinase (AMPK), and modulated the expression of genes involved in lipid metabolism towards lipid breakdown in differentiated adipocytes. In mouse model, oral administration of foenumoside B (10 mg/kg/day for 6 weeks) reduced HFD-induced body weight gain significantly without affecting food intake. Treatment of foenumoside B suppressed lipid accumulation in white adipose tissues and the liver, and lowered blood levels of glucose, triglycerides, ALT, and AST in HFD-induced obese mice. Consistent with the in vitro results, foenumoside B activated AMPK signaling, suppressed the expression of lipogenic genes, and enhanced the expression of lipolytic genes in vivo. Foenumoside B also blocked HFD-induced proinflammatory cytokine production in adipose tissue, suggesting its protective role against insulin resistance. Taken together, these findings demonstrate that foenumoside B represents the anti-obesity effects of L. foenum-graecum, and suggest therapeutic potential of foenumoside B in obesity and obesity-related metabolic diseases.